Bank of New York Mellon’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.22M Buy
107,635
+4,105
+4% +$46.4K ﹤0.01% 3010
2025
Q1
$1.19M Buy
103,530
+4,983
+5% +$57.5K ﹤0.01% 2945
2024
Q4
$835K Sell
98,547
-7,064
-7% -$59.8K ﹤0.01% 3244
2024
Q3
$1.22M Sell
105,611
-29,989
-22% -$347K ﹤0.01% 3015
2024
Q2
$1.6M Buy
135,600
+23,547
+21% +$277K ﹤0.01% 2920
2024
Q1
$1.33M Buy
112,053
+11,360
+11% +$135K ﹤0.01% 2993
2023
Q4
$1.23M Buy
100,693
+16,384
+19% +$201K ﹤0.01% 3081
2023
Q3
$812K Buy
84,309
+1,508
+2% +$14.5K ﹤0.01% 3281
2023
Q2
$745K Sell
82,801
-210
-0.3% -$1.89K ﹤0.01% 3375
2023
Q1
$652K Sell
83,011
-7
-0% -$55 ﹤0.01% 3348
2022
Q4
$561K Buy
83,018
+286
+0.3% +$1.93K ﹤0.01% 3483
2022
Q3
$1.2M Buy
82,732
+9,597
+13% +$139K ﹤0.01% 3113
2022
Q2
$719K Buy
73,135
+3,565
+5% +$35K ﹤0.01% 3367
2022
Q1
$1.03M Buy
69,570
+3,838
+6% +$56.6K ﹤0.01% 3299
2021
Q4
$870K Sell
65,732
-7,504
-10% -$99.3K ﹤0.01% 3465
2021
Q3
$1.28M Sell
73,236
-12,444
-15% -$217K ﹤0.01% 3250
2021
Q2
$2.05M Sell
85,680
-24,824
-22% -$595K ﹤0.01% 2963
2021
Q1
$2.84M Buy
110,504
+65,175
+144% +$1.67M ﹤0.01% 2719
2020
Q4
$861K Buy
45,329
+3,250
+8% +$61.7K ﹤0.01% 3337
2020
Q3
$529K Sell
42,079
-101
-0.2% -$1.27K ﹤0.01% 3460
2020
Q2
$511K Buy
42,180
+7,111
+20% +$86.1K ﹤0.01% 3456
2020
Q1
$268K Buy
35,069
+70
+0.2% +$535 ﹤0.01% 3646
2019
Q4
$623K Sell
34,999
-1,900
-5% -$33.8K ﹤0.01% 3473
2019
Q3
$428K Sell
36,899
-2,187
-6% -$25.4K ﹤0.01% 3616
2019
Q2
$865K Buy
39,086
+31,958
+448% +$707K ﹤0.01% 3310
2019
Q1
$204K Buy
+7,128
New +$204K ﹤0.01% 3873
2016
Q4
Sell
-1,018
Closed -$7K 4286
2016
Q3
$7K Sell
1,018
-91
-8% -$626 ﹤0.01% 4252
2016
Q2
$10K Sell
1,109
-1,681
-60% -$15.2K ﹤0.01% 4288
2016
Q1
$25K Hold
2,790
﹤0.01% 4157
2015
Q4
$141K Buy
2,790
+120
+4% +$6.07K ﹤0.01% 3950
2015
Q3
$133K Sell
2,670
-639
-19% -$31.8K ﹤0.01% 3988
2015
Q2
$331K Buy
+3,309
New +$331K ﹤0.01% 3756